Sol-Gel Technologies, Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Ness Ziona Israel (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2012
NCT00940992
First Marketed Drug
2021
tretinoin (Retin-A)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

SOL-GEL TECHNOLOGIES | Sol-Gel Technologies, Ltd.

Active Ingredients

Marketed Drugs (2)

benzoyl peroxide (clearasil) (2021)

tretinoin (Retin-A) (2021)

Drugs in Phase 3 Trials (4)

benzoyl peroxide (clearasil) (9 trials)

fluorouracil (efudex) (1 trial)

saridegib (1 trial)

tretinoin (Retin-A) (3 trials)

Drugs in Phase 2 Trials (1)

butenafine (mentax) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 3)

Keratosis (Phase 3)

Keratosis, Actinic (Phase 3)

Rosacea (Phase 3)

Tinea (Phase 2)

Tinea Pedis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 5